van de Meeberg Maartje M, Derikx Lauranne A A P, Sinnige Harm A M, Nooijen Peet, Schipper D Lucette, Nissen Loes H C
Maartje M van de Meeberg, Lauranne AAP Derikx, D Lucette Schipper, Loes HC Nissen, Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 5200 ME 's-Hertogenbosch, The Netherlands.
World J Gastroenterol. 2016 Dec 21;22(47):10465-10470. doi: 10.3748/wjg.v22.i47.10465.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare non-Hodgkin lymphoma with a high mortality rate. Higher incidence is reported in patients with inflammatory bowel disease, specifically in male patients that are younger than 35 years, and have been treated with thiopurine and tumor necrosis factor (TNF)-α inhibitor combination therapy for over 2 years. In this case report we describe a 47-year-old patient with Crohn's disease (CD) who developed HSTCL after having been treated with thiopurine monotherapy for 14 years. To our best knowledge, only eleven cases exist of patients with CD who developed HSTCL while on thiopurine monotherapy. We report the first patient with CD, older than 35 years, who developed HSTCL while on thiopurine monotherapy. This emphasizes that HSTCL risk is not limited to young men receiving both thiopurines and TNF-α inhibitors.
肝脾T细胞淋巴瘤（HSTCL）是一种罕见的非霍奇金淋巴瘤，死亡率很高。据报道，炎症性肠病患者的发病率较高，特别是年龄小于35岁的男性患者，并且接受硫嘌呤和肿瘤坏死因子（TNF）-α抑制剂联合治疗超过2年的患者。在本病例报告中，我们描述了一名47岁的克罗恩病（CD）患者，在接受硫嘌呤单药治疗14年后发生了HSTCL。据我们所知，仅有11例CD患者在接受硫嘌呤单药治疗时发生了HSTCL。我们报告了首例年龄大于35岁的CD患者，在接受硫嘌呤单药治疗时发生了HSTCL。这强调了HSTCL的风险不仅限于同时接受硫嘌呤和TNF-α抑制剂的年轻男性。
